GHRH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Besides the potential newer effects as antibiotics or anti-cancers, P.arhizus has traditionally been used for wound healing and hemorragic disorders in places such as Italy and regions of Africa. Looking beyond the composition of P.arhizus, the species has a number of confirmed uses as well as theoretical potentials. A traditional use of the fungus is as a dyeing agent (hence "dyeball") of assorted textiles, producing a range of pigments varying in description from yellow to shades of brown. P.arhizus has also has been mentioned for its use in forestry and land restoration as a mycorrhizal agent for inoculation projects, and some online gardening websites mention its positive effects on plant performance.
These 35 are known as primordial radionuclides. Well-known examples are uranium and thorium, but also included are naturally occurring long-lived radioisotopes, such as potassium-40. Each of the heavy primordial radionuclides participates in one of the four decay chains.
In industry, a similar reaction is carried out at high pressure and temperature in the presence of quaternary ammonium or phosphonium salts as a catalyst. Reaction of ethylene oxide with formaldehyde at 80–150 °C in the presence of a catalyst leads to the formation of 1,3-dioxolane:
great-granddaughter of Joseph Hertz (Chief Rabbi of the British Empire) Chaim Herzog(Hebrew: חיים הרצוג; 17 September 1918 – 17 April 1997) Northern-Irish-born Israeli politician, general, lawyer and author of over five books on the Arab-Israeli conflict, who served as the sixth President of Israel; born in Belfast, raised in Dublin, the son of Ireland's Chief Rabbi Yitzhak HaLevi Herzog, he immigrated to Mandatory Palestine in 1935 and served in Haganah Jewish paramilitary group during the 1936–1939 Arab revolt; returned to Palestine after the war and, following the end of the British Mandate and Israel's Declaration of Independence in 1948, fought in the Battles of Latrun during the 1948 Arab–Israeli War; retired from Israel Defence Forces in 1962 with rank of major-general.His son Isaac Herzog is the incumbent President of Israel, the first father–son pair to serve as the nation's president, and led the Israeli Labor Party and the parliamentary Opposition in the Knesset between 2013 and 2017.
Sources: en.wikipedia.org
The particular series of amino acids that form a protein is known as that protein's primary structure. This sequence is determined by the genetic makeup of the individual. It specifies the order of side-chain groups along the linear polypeptide "backbone". Proteins have two types of well-classified, frequently occurring elements of local structure defined by a particular pattern of hydrogen bonds along the backbone: alpha helix and beta sheet. Their number and arrangement is called the secondary structure of the protein. Alpha helices are regular spirals stabilized by hydrogen bonds between the backbone CO group (carbonyl) of one amino acid residue and the backbone NH group (amide) of the i+4 residue. The spiral has about 3.6 amino acids per turn, and the amino acid side chains stick out from the cylinder of the helix. Beta pleated sheets are formed by backbone hydrogen bonds between individual beta strands each of which is in an "extended", or fully stretched-out, conformation. The strands may lie parallel or antiparallel to each other, and the side-chain direction alternates above and below the sheet. Hemoglobin contains only helices, natural silk is formed of beta pleated sheets, and many enzymes have a pattern of alternating helices and beta-strands. The secondary-structure elements are connected by "loop" or "coil" regions of non-repetitive conformation, which are sometimes quite mobile or disordered but usually adopt a well-defined, stable arrangement. The overall, compact, 3D structure of a protein is termed its tertiary structure or its "fold".
== History == The Mediterranean region contains the earliest archeological evidence of human use; the oldest known seeds date back to more than 5000 BC in the Neolithic age with purposes such as food, anaesthetics, and ritual. Evidence from ancient Greece indicates that opium was consumed in several ways, including inhalation of vapors, suppositories, medical poultices, and as a combination with hemlock for suicide. Opium is mentioned in the most important medical texts of the ancient and medieval world, including the Ebers Papyrus and the writings of Dioscorides, Galen, and Avicenna. Widespread medical use of unprocessed opium continued through the American Civil War before giving way to morphine and its successors, which could be injected at a precisely controlled dosage.
== Problems faced in drug delivery == Other problems persist besides just simply getting through the blood–brain barrier. The first of these is that a lot of times, even if a compound transverses the barrier, it does not do it in a way that the drug is in a therapeutically relevant concentration. This can have many causes, the most simple being that the way the drug was produced only allows a small amount to pass through the barrier. Another cause of this would be the binding to other proteins in the body rendering the drug ineffective to either be therapeutically active or able to pass through the barrier with the adhered protein. Another problem that must be accounted for is the presence of enzymes in the brain tissue that could render the drug inactive. The drug may be able to pass through the membrane fine, but will be deconstructed once it is inside the brain tissue rendering it useless. All of these are problems that must be addressed and accounted for in trying to deliver effective drug solutions to the brain tissue.
==== 1935–1949 ==== Teva Pharmaceutical Industries took its present form through the efforts of Günther Friedländer and his aunt Else Kober on May 1, 1935. The original registration was under the name Teva Middle East Pharmaceutical & Chemical Works Co. Ltd. in Jerusalem, then part of Mandatory Palestine. Friedländer was a German pharmacist, botanist and pharmacognosist, who immigrated to Mandatory Palestine in 1934. The company was built with an investment of £4,900, which came from the family's own capital and partly from loans from other German immigrants. Capital shortage led to the joining of the banker Alfred Feuchtwanger as a partner in Teva, who received 33% of the shares in return for his investment. Friedländer's business philosophy opined that the pharmaceutical industry has a reliable basis in difficult economic times, since "A Jewish mother will always buy medicine for her children". In the Second World War, the company provided medicine to the allied forces and in particular to the British army present in the Middle East. After the war, Sir Alan Gordon Cunningham, the last of the High Commissioners for Palestine and Transjordan, visited Teva on behalf of the Secretary of State for the Colonies. His visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development. During Mandatory Palestine, Teva exported its medical products to Arab countries. In 1941, Friedländer presented Teva products in an exhibition held in Cairo, Egypt.
In the final step of the biosynthesis, two molecules of 6,7-dimethyl-8-ribityllumazine are combined by the enzyme riboflavin synthase in a dismutation reaction. This generates one molecule of riboflavin and one of 5-amino-6-(D-ribitylamino) uracil. The latter is recycled to the previous reaction in the sequence.
Sources: en.wikipedia.org
In addition to ribosome dimerization, the joining of the two ribosomal subunits can be blocked by RsfS (formerly called RsfA or YbeB). RsfS binds to L14, a protein of the large ribosomal subunit, and thereby blocks joining of the small subunit to form a functional 70S ribosome, slowing down or blocking translation entirely. RsfS proteins are found in almost all eubacteria (but not archaea) and homologs are present in mitochondria and chloroplasts (where they are called MALSU1 and iojap, respectively). However, it is not known yet how the expression or activity of RsfS is regulated. Another ribosome-dissociation factor in Escherichia coli is HflX, previously a GTPase of unknown function. Zhang et al. (2015) showed that HflX is a heat shock–induced ribosome-splitting factor capable of dissociating vacant as well as mRNA-associated ribosomes. The N-terminal effector domain of HflX binds to the peptidyl transferase center in a strikingly similar manner as that of the class I release factors and induces dramatic conformational changes in central intersubunit bridges, thus promoting subunit dissociation. Accordingly, loss of HflX results in an increase in stalled ribosomes upon heat shock and possibly other stress conditions.
Cardiovascular–kidney–metabolic syndrome (CKM syndrome) is a multisystem disorder of the metabolic, renal and cardiovascular systems. (The term CKM syndrome was first introduced by the American Heart Association in 2023.) This syndrome is the result of interactions between metabolic risk factors, e.g., prediabetes, type 2 diabetes, insulin resistance in normally insulin-sensitive tissues, systemic inflammation, metabolic dysfunction–associated steatotic liver disease (i.e., non-alcoholic fatty liver disease due to the accumulation of excessive fat levels in the liver), dyslipidemia, and obesity. Acting alone or interacting with each other, these abnormalities can promote chronic kidney and cardiovascular disorders and thereby lead to increases in morbidity and mortality rates.
== Related enzymes == Prophenoloxidase is a modified form of the complement response found in some invertebrates, including insects, crabs and worms. Hemocyanin is homologous to the phenol oxidases (e.g. tyrosinase) since both enzymes sharing type copper active site coordination. Hemocyanin also exhibits PPO activity, but with slowed kinetics from greater steric bulk at the active site. Partial denaturation actually improves hemocyanin's PPO activity by providing greater access to the active site. Aureusidin synthase is homologous to plant polyphenol oxidase, but contains certain significant modifications. Aurone synthase catalyzes the formation of aurones. Aurone synthase purified from Coreopsis grandiflora shows weak tyrosinase activity against isoliquiritigenin, but the enzyme does not react with the classic tyrosinase substrates l-tyrosine and tyramine and must therefore be classified as catechol oxidase. Laccase, a multi-copper oxidase, is often considered a subclass of polyphenol oxidase. Laccase and polyphenol oxidase differ in the type of substrates that they catalyse. Catachol oxidase (a type of polyphenol oxidase) catalyses the oxidation of ortho-diphenols to ortho-quinones. Tyrosinase (another type of polyphenol oxidase), catalyses both the oxidation of monophenols to ortho-diphenols, and the subsequent oxidation of ortho-diphenols to ortho-quinones. Laccase, in contrast, catalyses the oxidation of para-diphenols to para-quinones.
== External links == glycosciences.de This site provides databases and bioinformatics tools for glycobiology and glycomics. GlycomeDB, A carbohydrate structure metadatabase GlycoBase A web HPLC/UPLC resource that contains elution positions expressed as glucose unit values. ProGlycAn A short introduction to glycan analysis and a nomenclature for N-Glycans Emanual Maverakis; et al. "Glycans in the immune system and The Altered Glycan Theory of Autoimmunity" (PDF). CD BioGlyco This site provides database and tools in the field of glycomics, from glycan release, separation, and purification, glycan derivatization to glycan characterization and quantification.
=== Glyoxylate scenario === Eschenmoser also proposed a parallel scenario where the connections between prebiotic reactions would be connected by glyoxylate, a simple α-ketoacid, produced by HCN oligomerization and hydrolysis. In this work, Eschenmoser proposes potential schemes to generate both informational oligomers and other key autocatalytic reactions from plausible one-carbon sources (HCN, CO, CO2). The Krishnamurthy group at Scripps experimentally expanded on this theory. In mild aqueous conditions, they demonstrated that the reaction of glyoxylate and pyruvate can produce a series of α-ketoacid intermediates constituting the reductive tricarboxylic acid (TCA) cycle. This reaction proceeded without metal or enzyme catalysts as glyoxylate acted as both the carbon source and reducing agent in the reaction. Similarly, the Moran group have also reported pyruvate and glyoxylate can react in warm iron-rich water to produce TCA intermediates and some amino acids. Their work has successfully reconstructed 9 out of 11 TCA intermediates and 5 universal metabolic precursors. Additional experimental analysis is needed to connect this scenario to modern metabolism.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.